Quantum Market Cap
← Back to Dashboard
Price History
Compare vs

Dashed lines mark market-closed periods (overnight, weekends & holidays)

Jul 22Jul 23Jul 24Jul 27Jul 28Jul 29$0.70$0.75$0.80$0.85$0.75$0.84$0.70

About Quantum-Si

Quantum-Si (QSI) has a market cap of $162.45M as of August 2026 — #12 of the 12 pure-play quantum computing stocks by market value.

Quantum-Si is building a semiconductor chip-based platform for single-molecule protein sequencing using quantum-detection technology. Its Platinum Pro system targets proteomics research; next-gen Proteus instrument targets late 2026 commercial launch.

Sector

Healthcare

Industry

Medical Devices

Employees

145

Founded

2017

Headquarters

Guilford, CT

Shares Outstanding

217.8M

Quantum Division

https://www.quantum-si.com/technology/

Visit ↗

Quantum Technology

Roadmap Target

Proteus commercial launch late 2026 (18+ amino acids, ~1,000× throughput); 20 of 20 amino acids by 2027

Quantum-Si is NOT a quantum computing company. It uses quantum tunneling detection in a CMOS semiconductor chip for single-molecule protein sequencing (proteomics). Current product: Platinum Pro (launched Jan 2025, V4 kit detects 17 of 20 amino acids). Next-gen: Proteus instrument (late 2026 commercial launch target) — 18+ amino acids at launch, tens of millions of peptides per experiment (vs. tens of thousands on Platinum Pro), ~90 min run time. Successful sequencing on integrated Proteus instruments (April 2026, KinetIQ Array dev kit, 17 amino acids); Early Access Program summer 2026.

Dilution Risk29 shelf or ATM filings on record (S-3/424B/SUPPL). These filings can provide a channel for new share sales.
66.7% Daily Short Vol66.7% of today's reported volume was short selling (FINRA daily data). Normal range is 40–55%; above 60% signals unusually heavy short-side activity.

Cash Position & Runway

Total Cash

$127.38M

TTM Cash Burn

$94.72M

per year (TTM)

Cash Runway

16 mo

Total Debt

$0.00

Dilution Risk: With 16 months of runway, Quantum-Si will likely need to raise additional capital through equity offerings (diluting existing shareholders) or debt financing within the next two years.

Quarterly Operating Cash Flow

202120222023202420252026$-30M$-25M$-20M$-15M$-10M

Red bars = cash burn (negative operating CF). Green = cash-flow positive. Source: SEC EDGAR 10-Q filings.

Financial Metrics (Annual)

Total Revenue

$2.44M

Revenue Growth (YoY)

-20.3%

Gross Margins

47.33%

Operating Margins

-4765.97%

Net Margins

-4160.06%

Total Debt

$0.00

P/E Ratio (TTM)

EPS (TTM)

$-0.5100

Price / Book

0.81

Earnings Per Share (TTM)

EPS (TTM)

$-0.5100

Unprofitable

P/E Ratio

Price / Book

0.81

Price-to-Book

Returns vs S&P 500

1Y

QSI-51.3%
S&P 500+15.6%
vs Index-66.8%

3Y

QSI-79.3%
S&P 500+63.3%
vs Index-142.6%

5Y

QSI-92.4%
S&P 500+65.1%
vs Index-157.6%

Source: price_history vs SPY · Periods where price history is unavailable are hidden

Government Contracts & Grants

Total Obligated

$381.06K

Awards Found

5

USAspending ↗
Included: Federal contracts & grants (USAspending.gov, prime recipient only).
Excluded: Subcontracts, state/local funding, classified contracts, awards <~$30k.

Source: USAspending.gov · Updated quarterly

Shares Outstanding History

Share-count history will appear here once Quantum-Si has filed enough reports with the SEC to chart a trend. Recently listed companies start with a single data point.

Daily Short Volume (FINRA)

Latest Short Vol %

66.7%

2026-07-29

Short Volume

2,001,134

DateShort VolTotal VolShort %
2026-07-292,001,1343,001,32966.7%
2026-07-27357,898695,78151.4%
2026-07-241,145,1441,811,12863.2%
2026-07-221,044,7752,008,32052%
2026-07-17852,3921,628,53352.3%
2026-07-161,594,4762,300,89069.3%
2026-07-15646,7171,277,35950.6%
2026-07-131,242,0502,231,55455.7%
2026-07-101,250,0431,988,39562.9%
2026-07-09704,7451,687,31741.8%

Source: FINRA CNMS · Not the same as total short interest (outstanding positions) · Updated daily

StockTwits Sentiment

77.8%
22.2%
▲ 7 Bullish▼ 2 Bearish9 scored

Source: StockTwits · last 30 messages · updated every 4h

Press Releases

GlobeNewswire ↗
Jul 27, 2026Quantum-Si to Report Second Quarter 2026 Financial Results on August 13, 2026GlobeNewswireJul 27, 2026Quantum-Si to Report Second Quarter 2026 Financial Results on August 13, 2026NewsroomJun 16, 2026Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NewsroomJun 10, 2026Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™NewsroomJun 3, 2026Quantum-Si Announces the Expansion of the Proteus™ RoadshowNewsroomMay 13, 2026Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NewsroomMay 7, 2026Quantum-Si Reports First Quarter 2026 Financial Results and Highlights Proteus™ Development MilestonesNewsroomMay 1, 2026Quantum-Si to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQNewsroomApr 28, 2026Quantum-Si Announces Successful Sequencing on Integrated Proteus™ InstrumentsNewsroomApr 16, 2026Quantum-Si to Report First Quarter 2026 Financial Results on May 7, 2026NewsroomApr 15, 2026Quantum-Si Announces Two Customer Posters to be Presented at the American Association of Cancer Research Annual MeetingNewsroomApr 14, 2026Quantum-Si Announces New Manuscript Demonstrating the Value of Single-molecule Protein Sequencing to Aid in Identifying New Cancer Treatment StrategiesNewsroomApr 10, 2026Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NewsroomApr 8, 2026Quantum-Si Announces First Customer Samples Tested on the Proteus™ Prototype SystemNewsroomApr 6, 2026Quantum-Si Announces the Start of the Proteus™ RoadshowNewsroomMar 13, 2026Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NewsroomMar 3, 2026Quantum-Si Reports Fourth Quarter and Full Year 2025 Financial ResultsNewsroomFeb 13, 2026Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NewsroomFeb 10, 2026Quantum-Si to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026NewsroomFeb 5, 2026Quantum-Si Announces the Release of Two New Manuscripts Demonstrating the Value of Single-Molecule Protein Sequencing in Clinical Proteomics and Pathogen & Toxin DetectionNewsroomDec 22, 2025Quantum-Si Announces Launch of New Version 3 Library Preparation Kit and a Suite of Data Analysis Tool EnhancementsNewsroomDec 15, 2025Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NewsroomNov 20, 2025Quantum-Si Highlights Significant Development Advancements for Proteus™ and Industry Leading Technology Pipeline at Investor & Analyst DayNewsroomNov 19, 2025Quantum-Si to Highlight Significant Proteus™ Platform Development Progress and Provide Insights into the Company’s Industry Leading Technology Pipeline at Investor & Analyst DayNewsroomNov 5, 2025Quantum-Si Reports Third Quarter 2025 Financial ResultsNewsroomOct 20, 2025Quantum-Si to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumNewsroom

Source: Company newsroom (direct) + wire services (GlobeNewswire, PR Newswire) via Finnhub

News Mention Volume (30 days)

2026-07-27024

Articles indexed every 4h · Sentiment scored via Loughran-McDonald financial word lists (bullish/bearish keyword frequency). Not ML-based — scores reflect word presence only and may not capture context or sarcasm.

SEC Filings & Earnings Reports

View annual, quarterly, and material-event filings on SEC EDGAR

SEC EDGAR ↗
Financial Story

FY 2025

Quantum-Si posts ~$11M revenue in FY2025 as net losses persist; Platinum Pro launched, Proteus on track for 2026

·Platinum Pro benchtop sequencer launched January 2025 with first shipments in March 2025, priced at ~$120K vs. Platinum at ~$85K.
·North American distribution agreement with Avantor announced November 2024 to broaden Platinum Pro commercial reach.
·Proteus next-gen platform (anticipated ~$8B addressable market) on track for commercial launch by end of 2026, with ~80M features per chip and full workflow automation.

Management expects Proteus to launch commercially by end of 2026; international distribution network expansion planned for 2026 to support Proteus market awareness.

FY 2024

Revenue

$3.10M

▲ 186.5% YoY

Net Income

-$101.00M

Quantum-Si posts $3.1M revenue in FY2024 first full commercial year, net loss narrows slightly to $101M

·Full commercial launch of Platinum instrument began Q2 2024; revenue jumped to $3.1M from $1.1M in FY2023 and zero in FY2022.
·Platinum Pro launched January 2025 (~$120K list price); North American distribution agreement signed with Avantor in Nov 2024.
·Next-gen 'Proteus' platform roadmap announced Nov 2024, targeting higher throughput and broader proteomics workflow automation.

Company targeting broader commercial adoption via Platinum Pro shipments (Q1 2025), Avantor distribution ramp, and 18+ international partners; longer-term growth anchored on next-gen Proteus platform. Continued losses expected as R&D and commercialization spending remains elevated.

FY 2023

Revenue

$1.08M

Net Income

-$95.96M

Cash

$133.86M

Quantum-Si posts first-ever $1.1M revenue but burns $96M as pre-commercial losses persist

·First commercial revenue recognized in FY2023 ($1.1M) following Platinum instrument launch and shipments beginning January 2023.
·Net loss improved 27.5% YoY to $96M, aided by $5.6M marketable securities gain and $9.5M dividend income; no goodwill impairment vs $9.5M charge in 2022.
·Carbon sample prep instrument development paused in Oct 2023; contract manufacturer dispute filed in Texas (refiled Minnesota Jan 2024) — financial exposure indeterminate.

Management expects cash and marketable securities of $257.7M to fund operations for at least 12 months. Continued negative operating cash flows anticipated until commercial scale is achieved. ATM offering of up to $75M available but unused. Capital expenditures expected to remain ~$4.5M annually.

FY 2022

Net Income

-$132.44M

Cash

$351.30M

Quantum-Si burns $132M in FY2022 with zero revenue; $351M cash runway intact

·Platinum NGPS instrument launched December 2022 with commercial shipments beginning January 2023 — first revenue-generating milestone for the company.
·Full $9.5M goodwill impairment taken in Q4 2022 on Majelac acquisition; $20.1M in unrealized/realized losses on marketable securities added to losses.
·Post-period restructuring announced January 2023 cutting ~12% of workforce with ~$1M severance cost to reduce cash burn.

Management expects to launch Carbon automated sample prep instrument in 2023 and believes existing $351M in cash and securities is sufficient for at least 12 months. Restructuring targets cost reduction; however, negative operating cash flows are expected to continue for the foreseeable future.

FY 2021

Net Income

-$94.99M

Cash

$471.30M

Quantum-Si burns $95M in FY2021 with zero revenue; SPAC deal nets $511M cash war chest

·Completed SPAC Business Combination with HighCape on June 10, 2021, raising ~$511.2M; listed on Nasdaq as QSI with $471.3M in cash and marketable securities at year-end.
·Acquired Majelac Technologies for ~$8.8M (cash + stock) to bring semiconductor chip assembly in-house ahead of planned commercial launch in H2 2022.
·CEO John Stark departed February 2022; founder Dr. Jonathan Rothberg named Interim CEO with no additional compensation; commercial product launch targeted H2 2022.

Company targets commercial launch of Platinum NGPS and Carbon sample prep instruments in H2 2022 (RUO); expects continued heavy spending on R&D, sales/marketing, and headcount build-out; believes $471.3M in cash/securities sufficient for at least 12 months of operations.

FY 2020

Revenue

$0.00

Net Income

-$263.14K

Cash

$1.03M

HighCape SPAC raised $115M in IPO, seeking life sciences acquisition by Sept 2022

·Completed $115M IPO on Sept 9, 2020 (11.5M units at $10.00); full overallotment exercised; $115M placed in Trust Account invested in U.S. Treasuries.
·Signed Business Combination Agreement with Quantum-Si on Feb 18, 2021; PIPE financing of ~$425M committed at $10.00/share.
·No revenues or operations; net loss of $263,139 driven entirely by formation and G&A costs, partially offset by $2,152 Trust interest income.

Pending closing of Quantum-Si Business Combination; $425M PIPE financing secured. If combination fails, Trust liquidated and warrants expire worthless.

10-K · 10-Q · 20-F · 40-F · 6-K filings

All Filings ↗
Date FiledFormPeriod Covered
2026-05-0710-Q2026-03-31EDGAR ↗
2026-03-0310-K2025-12-31EDGAR ↗
2025-11-0510-Q2025-09-30EDGAR ↗
2025-08-0510-Q2025-06-30EDGAR ↗
2025-05-1510-Q2025-03-31EDGAR ↗
2025-03-0310-K2024-12-31EDGAR ↗
2024-11-1210-Q2024-09-30EDGAR ↗
2024-08-0710-Q2024-06-30EDGAR ↗
2024-05-0910-Q2024-03-31EDGAR ↗
2024-02-2910-K2023-12-31EDGAR ↗
2023-11-0910-Q2023-09-30EDGAR ↗
2023-08-0710-Q2023-06-30EDGAR ↗
2023-05-1110-Q2023-03-31EDGAR ↗
2023-03-1710-K2022-12-31EDGAR ↗
2022-11-0810-Q2022-09-30EDGAR ↗
2022-08-0810-Q2022-06-30EDGAR ↗
2022-05-1010-Q2022-03-31EDGAR ↗
2022-03-0110-K2021-12-31EDGAR ↗
2021-11-1510-Q2021-09-30EDGAR ↗
2021-08-1610-Q2021-06-30EDGAR ↗
2021-06-1010-Q/A2021-03-31EDGAR ↗
2021-05-2410-Q2021-03-31EDGAR ↗
2021-05-1010-K/A2020-12-31EDGAR ↗
2021-03-3010-K2020-12-31EDGAR ↗
2020-11-1310-Q2020-09-30EDGAR ↗

Source: SEC EDGAR · Annual: 10-K / 20-F / 40-F · Quarterly: 10-Q / 6-K · AI summaries generated automatically

Market Events

Earnings releases, contracts, leadership changes, offerings

All 8-Ks ↗
2026-07-24
8-K
Pending summary…
2026-06-24
Agreement
Quantum-Si Incorporated entered into a 10-year lease agreement on June 18, 2026, with Sterling City Science South Development, LLC for approximately 54,374 square feet of office, laboratory, and manufacturing space at 9955 Pacific Heights Boulevard, San Diego, California, anticipated to commence around September 1, 2027. The lease carries an initial monthly base rent of approximately $315,369 ($5.80/sq ft), escalating ~3% annually, with 20 months of rent abatement and a landlord tenant improvement allowance of up to $17.1 million. The company provided prepaid rent of ~$434,448 and a $2.1 million letter-of-credit security deposit upon signing, and has a one-time option to extend the lease for an additional five years.
2026-05-15
8-K
Quantum-SI Incorporated (QSI) held its Annual Meeting on May 15, 2026, at which approximately 84.59% of total voting power was represented. Shareholders reelected all ten director nominees to serve until the 2027 annual meeting, ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026, and approved the advisory vote on named executive officer compensation. All three proposals passed with strong majorities, with broker non-votes totaling 48,912,907 across each proposal.
2026-05-07
Earnings
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on May 7, 2026, disclosing its financial results for the first quarter ended March 31, 2026, along with a business update. The filing was signed by CFO Jeffry Keyes and includes a press release (Exhibit 99.1) and a non-GAAP financial measures disclosure (Exhibit 99.2). No specific revenue or earnings figures were included in the filing itself, as the detailed results are contained in the attached press release.
2026-03-03
Earnings
Quantum-Si Incorporated (QSI) filed an 8-K on March 3, 2026, disclosing its financial results for the fourth quarter and full year ended December 31, 2025. The filing, signed by CFO Jeffry Keyes, accompanied a press release (Exhibit 99.1) providing the earnings results and a business update. No specific financial figures were included in the 8-K body itself, with detailed results contained in the attached press release.
2025-12-29
IR Event
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on December 29, 2025, disclosing under Regulation FD that it posted an updated corporate presentation to its investor relations website. The filing, signed by CFO Jeffry Keyes, furnishes the presentation as Exhibit 99.1 and clarifies it is not deemed "filed" for Exchange Act liability purposes. No financial transactions, leadership changes, or specific financial figures were disclosed.
2025-11-20
IR Event
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on November 20, 2025, disclosing that it held an Investor & Analyst Day presentation on November 19, 2025. The presentation, furnished as Exhibit 99.1 and signed by CFO Jeffry Keyes, is available on the company's investor relations website along with a webcast replay. No financial figures were disclosed in the filing itself, as the submission serves solely as a Regulation FD disclosure of the presentation materials.
2025-11-05
Earnings
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on November 5, 2025, disclosing its financial results for the three and nine months ended September 30, 2025, along with a business update. The filing was signed by CFO Jeffry Keyes and includes a press release (Exhibit 99.1) and a non-GAAP financial measures explanation (Exhibit 99.2). No specific revenue or earnings figures were included in the filing body itself, as the detailed results are contained in the attached press release.
2025-09-29
Offering
On September 26, 2025, Quantum-Si Incorporated entered into an at-the-market Sales Agreement with Leerink Partners LLC, allowing the company to sell up to $100 million of its Class A common stock (par value $0.0001 per share) at its discretion over time. Leerink Partners will act as sales agent or principal, earning a commission of up to 3.0% of gross proceeds per share sold, plus up to $75,000 in reimbursed legal expenses. The offering is contingent on the effectiveness of a Form S-3 shelf registration statement filed with the SEC on the same date, and the company has no obligation to sell any shares.
2025-09-26
Agreement
Quantum-Si Incorporated entered into a Settlement and Mutual Release Agreement with Winchester Office LLC on September 23, 2025, to early-terminate a commercial office lease at 115 Munson Street, New Haven, CT, which was originally set to expire July 31, 2032. As consideration for the early termination, Quantum-Si agreed to pay a net termination fee of approximately $10.15 million (an $11 million fee less a $272,618.16 rent credit and the surrender of a $573,214.50 security deposit). The company is relieved of all further rent obligations as of the Early Termination Date of September 23, 2025.
2025-08-08
AgreementIR Event
Quantum-Si Incorporated filed an 8-K on August 8, 2025, disclosing under Regulation FD that it posted an updated corporate presentation to its investor relations website. The filing was signed by CFO Jeffry Keyes and includes the presentation as Exhibit 99.1. No financial transactions, agreements, or material business changes were announced; the filing serves solely as an informational update to the investment community.
2025-08-05
Earnings
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on August 5, 2025, disclosing its financial results for the three and six months ended June 30, 2025, along with a business update. The press release was issued by the company and the filing was signed by CFO Jeffry Keyes. No specific revenue or earnings figures were included in the 8-K body itself; the detailed results are contained in the attached Exhibit 99.1 press release.
2025-07-07
OfferingIR Event
Quantum-Si Incorporated (Nasdaq: QSI) entered into a securities purchase agreement on July 3, 2025 with an undisclosed institutional investor to sell 18,200,000 shares of Class A common stock at $1.67 per share and pre-funded warrants to purchase an additional 11,740,119 shares in a registered direct offering, with gross proceeds expected to be approximately $50 million before fees. A.G. P./Alliance Global Partners is acting as exclusive placement agent for a 6.0% cash fee, and the offering is expected to close on July 8, 2025. Concurrently, the company terminated its at-the-market equity distribution agreement with Canaccord Genuity LLC, originally dated December 11, 2024, and intends to use the net proceeds for development of its Proteus platform, commercialization, R&D, and general corporate purposes.
2025-05-19
8-K
Quantum-SI Incorporated held its Annual Meeting on May 16, 2025, with approximately 85% of total voting power represented. Shareholders voted on three proposals: all ten director nominees were reelected to serve until the 2026 annual meeting, PricewaterhouseCoopers LLP was ratified as the independent auditor for fiscal year ending December 31, 2025, and executive compensation was approved on an advisory basis. All proposals passed with strong majority support.
2025-05-15
Earnings
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on May 15, 2025, disclosing its financial results for the first quarter ended March 31, 2025, along with a business update. The filing was signed by CFO Jeffry Keyes and includes a press release (Exhibit 99.1) and a non-GAAP financial measures disclosure (Exhibit 99.2). No specific revenue or earnings figures were included in the filing itself, as the detailed results are contained in the attached press release.
2025-04-10
AgreementIR Event
Quantum-Si Incorporated filed an 8-K on April 10, 2025, disclosing under Regulation FD that it posted an updated corporate presentation to its investor relations website. The filing was signed by CFO Jeffry Keyes and includes the presentation as Exhibit 99.1. No financial transactions, agreements, or material business changes were announced; the filing solely serves to distribute updated investor communications.
2025-03-03
Earnings
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on March 3, 2025, disclosing its financial results for the fourth quarter and full year ended December 31, 2024. The filing, signed by CFO Jeffry Keyes, accompanied a press release and business update issued the same day. No specific revenue or earnings figures were included in the filing itself, with full details contained in the attached Exhibit 99.1 press release.
2025-01-06
OfferingIR Event
On January 3, 2025, Quantum-Si Incorporated entered into a securities purchase agreement with institutional investors to sell 15,625,000 shares of Class A common stock at $3.20 per share in a registered direct offering, expected to raise $50 million in gross proceeds before fees. A.G. P./Alliance Global Partners served as sole placement agent, earning a 6% cash fee on gross proceeds. The offering was expected to close on January 6, 2025, with proceeds earmarked for product development (including the Proteus platform), commercialization, R&D, and general corporate purposes.
2024-12-11
Offering
On December 11, 2024, Quantum-Si Incorporated entered into an Equity Distribution Agreement with Canaccord Genuity LLC to sell up to $75 million of Class A common stock through an at-the-market offering program, with Canaccord acting as sales agent at a commission of up to 3.0% of gross sales. Simultaneously, the company terminated its prior ATM agreement with Evercore Group L.L.C., originally dated August 11, 2023, under which no shares had been sold. The new offering is made under the company's existing shelf registration statement that became effective August 22, 2023.
2024-12-09
Listing Risk
Quantum-Si Incorporated disclosed that it has regained compliance with Nasdaq's minimum bid price requirement (Listing Rule 5450(a)(1)) as of December 4, 2024, after previously falling below the $1.00 per share threshold for 30 consecutive business days. Nasdaq's Listing Qualifications Staff notified the company on December 5, 2024, that the matter is closed. The company cautioned that failure to maintain compliance in the future could result in a new delisting notice.
2024-11-22
EarningsEquity Grant
On November 21, 2024, Quantum-Si Incorporated committed to a restructuring program to streamline operations and refocus resources toward future product development, including its Proteus platform, resulting in the termination of approximately 23% of its 187-person workforce. The company expects to incur one-time cash charges of approximately $2.3 million in 2024 and $0.3 million in the first half of 2025 for severance and benefits, plus roughly $0.2 million in non-cash stock option modification expenses. The restructuring is expected to be substantially complete by the end of Q4 2024, and the filing was signed by CFO Jeffry Keyes on November 22, 2024.
2024-11-21
IR Event
On November 20, 2024, Quantum-Si Incorporated (Nasdaq: QSI) held an Investor & Analyst Day, during which it presented a corporate slide deck to the investment community. The presentation, furnished as Exhibit 99.1 and available on the company's investor relations website, provides updates and summaries of its business. The filing was signed by General Counsel Christian LaPointe, Ph.D., and is disclosed under Regulation FD (Item 7.01), meaning it is furnished but not deemed "filed" for liability purposes under the Exchange Act.
2024-11-12
Earnings
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on November 12, 2024, disclosing its financial results for the three and nine months ended September 30, 2024, along with a business update. The filing was signed by CFO Jeffry Keyes and includes a press release (Exhibit 99.1) and a non-GAAP financial measures explanation (Exhibit 99.2). No specific revenue or earnings figures were included in the 8-K body itself, as the detailed results are contained in the attached press release.
2024-11-08
Listing Risk
Quantum-Si Incorporated (Nasdaq: QSI) received a written notice from Nasdaq on November 4, 2024, stating that the company's Class A common stock has failed to meet the minimum $1.00 bid price requirement after closing below that threshold for 30 consecutive business days. The company has 180 days until May 5, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. The notice does not immediately affect trading or business operations, but failure to regain compliance could ultimately result in delisting from The Nasdaq Global Market.
2024-08-27
Leadership
Quantum-Si Incorporated disclosed a leadership change in its commercial division. Grace Johnston, Ph.D. resigned as Chief Commercial Officer effective September 6, 2024, and Todd Bennett was appointed as her replacement, effective September 17, 2024. The filing was reported on August 21, 2024, and the press release announcing Bennett's appointment was dated August 27, 2024.
2024-08-13
IR Event
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on August 12, 2024, disclosing under Regulation FD that it posted an updated corporate presentation to its investor relations website. The presentation, filed as Exhibit 99.1 and signed by CFO Jeffry Keyes, is intended to provide the investment community with a business update and summary. The filing is furnished rather than filed, meaning it is not subject to liability under Section 18 of the Exchange Act.
2024-08-07
Earnings
Quantum-Si Incorporated filed an 8-K on August 7, 2024, disclosing its financial results for the three and six months ended June 30, 2024, along with a business update. The filing was signed by CFO Jeffry Keyes and includes a press release (Exhibit 99.1) and a non-GAAP financial measures disclosure (Exhibit 99.2). No specific financial figures were detailed within the 8-K itself, as the results were contained in the attached press release.
2024-06-25
IR Event
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on June 25, 2024, disclosing under Regulation FD that it posted an updated corporate presentation to its investor relations website. The presentation, filed as Exhibit 99.1 and signed by CFO Jeffry Keyes, is intended to provide business updates and summaries to the investment community. The filing is furnished, not filed, meaning it is not subject to liability under Section 18 of the Exchange Act.
2024-06-07
AgreementRestatement
On June 4, 2024, Quantum-Si Incorporated's Audit Committee dismissed Deloitte & Touche LLP as its independent auditor and appointed PricewaterhouseCoopers LLP (PwC) for the fiscal year ending December 31, 2024. The change was made without any disagreements with Deloitte, though two previously disclosed material weaknesses in internal controls over financial reporting were noted as reportable events. Deloitte confirmed its agreement with the company's disclosures in a letter dated June 7, 2024.
2024-05-30
Equity Grant
Quantum-Si Incorporated elected Charles "Chuck" Kummeth to its Board of Directors and appointed him as Chairperson, effective May 27, 2024, replacing Jonathan M. Rothberg, Ph.D., who remains a director. Kummeth, age 63 and formerly CEO of Bio-Techne Corporation, received a one-time special grant of stock options to purchase 527,777 shares of Class A common stock with an aggregate grant date fair value of $570,000, vesting in equal annual installments over three years. The Board also expanded its size from nine to ten members in connection with his appointment.
2024-05-24
8-K
On May 16, 2024, a putative class action lawsuit (Farzad v. HighCape Capital, et al.) was filed in the Delaware Court of Chancery against former officers and directors of HighCape Capital Acquisition Corp.—including Kevin Rakin, Matt Zuga, David Colpman, Robert Taub, and Antony Loebel—as well as Foresite Capital Management and Jonathan M. Rothberg, Ph.D. The suit alleges breach of fiduciary duty, aiding and abetting, and unjust enrichment related to the business combination between HighCape and Quantum-Si, claiming the deal resulted from a conflicted and unfair process that led to mispricing. The complaint seeks unspecified damages, attorneys' fees, and costs, with no assurance of a successful defense or adequate insurance coverage.
2024-05-17
8-K
Quantum-Si Incorporated held its 2024 annual meeting on May 15, 2024, at which stockholders approved amendments to the company's certificate of incorporation, including removing the cap on board size and adding an automatic conversion provision for Class B common stock effective June 10, 2028. The Charter Amendment was filed with the Delaware Secretary of State on May 16, 2024, and all nine director nominees were reelected, Deloitte & Touche LLP was ratified as auditor for fiscal year 2024, and executive compensation was approved on an advisory basis. Approximately 88.45% of total voting power was represented at the meeting, with Class B shares carrying 20 votes per share compared to one vote per share for Class A.
2024-05-09
Earnings
Quantum-Si Incorporated (QSI) filed an 8-K on May 9, 2024, disclosing its first quarter financial results for the period ended March 31, 2024, along with a business update. The filing was signed by CFO Jeffry Keyes and included a press release (Exhibit 99.1) and a non-GAAP financial measures document (Exhibit 99.2). Specific financial figures were not detailed in the 8-K itself but are contained in the attached press release.
2024-04-09
IR Event
Quantum-Si Incorporated filed an 8-K on April 9, 2024, disclosing under Regulation FD that it posted an updated corporate presentation to its investor relations website. The filing was signed by CFO Jeffry Keyes and the presentation is furnished as Exhibit 99.1. No financial transactions or material business changes were announced; the filing solely relates to routine investor communications.
2024-03-21
Listing Risk
Quantum-Si Incorporated appointed Paula Dowdy to its Board of Directors effective March 21, 2024, where she will serve until the company's next annual stockholder meeting. Dowdy, age 58, brings over 35 years of experience in commercial and operational roles, including former SVP/GM of EMEA at Illumina and over 20 years at Cisco Systems. She will receive standard non-employee director compensation under the company's existing policy and has been determined to be an independent director under Nasdaq listing rules.
2024-03-11
Equity Grant
Quantum-Si Incorporated disclosed amendments to performance-based stock option awards granted to CEO Jeffrey Hawkins and CFO Jeffry Keyes, effective March 15, 2024, to better align vesting conditions with current stock prices. Hawkins's options covering 2,780,000 total shares now vest in tranches tied to closing price thresholds of $6.00, $8.00, $10.00, and $12.00, while Keyes's options covering 1,000,000 total shares are subject to the same price targets, each requiring the threshold to be met for 20 out of 30 consecutive trading days within three years of the effective date. The Board approved Hawkins's amendments on March 10, 2024, and the Compensation Committee approved Keyes's amendments on March 8, 2024.
2024-02-29
Earnings
On February 29, 2024, Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K disclosing its financial results for the fourth quarter and full year ended December 31, 2023. The press release and business update were furnished as exhibits and signed by CFO Jeffry Keyes. No specific financial figures were included in the 8-K body itself, with the detailed results contained in the attached Exhibit 99.1.
2024-02-05
8-K
On February 5, 2024, Quantum-Si Incorporated (Nasdaq: QSI) announced the launch of new V2 Sequencing Kits for its Platinum protein sequencing instrument, expanding the platform by incorporating peptide barcodes and supporting new sample types. The disclosure was made under Regulation FD (Item 7.01) and Other Items (Item 8.01), with the filing signed by General Counsel Christian LaPointe, Ph.D. No financial figures were disclosed in connection with this product enhancement announcement.
2023-11-09
Earnings
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on November 9, 2023, disclosing its financial results for the third quarter ended September 30, 2023, along with a business update. The press release was issued by the company and the filing was signed by CFO Jeffry Keyes. No specific financial figures were included in the 8-K body itself, with full results provided in the attached Exhibit 99.1.
2023-09-21
8-K
Quantum-Si Incorporated appointed Amir Jafri, age 57 and founder/CEO of Immunicom, Inc., to its Board of Directors effective September 22, 2023, expanding the Board from eight to nine members. Jafri, deemed an independent director under Nasdaq rules, will serve until the company's next annual stockholder meeting and receive standard nonemployee director compensation. Separately, the Board also appointed Jack Kenny as Chairperson of the Nominating and Corporate Governance Committee on September 15, 2023.
2023-09-05
LeadershipEquity GrantAgreement
Quantum-Si Incorporated disclosed the departure of Patrick Schneider, Ph.D., its former President and Chief Operating Officer, whose employment ended on August 31, 2023. Under a Separation Agreement signed September 1, 2023, the company will pay Schneider $356,250 in separation pay, cover the employer portion of COBRA health insurance through up to May 31, 2024, and vest 291,666 stock options while forfeiting all remaining unvested options. The agreement also includes a release and waiver by Schneider.
2023-08-29
Equity GrantAgreement
Quantum-Si Incorporated announced on August 26, 2023 that it is undertaking an organizational restructuring, cutting approximately 16% of its workforce and expecting to incur roughly $2.5 million in severance charges and $0.3 million in non-cash stock option modification expenses through the end of 2023. Concurrent with the restructuring, President and COO Patrick Schneider, Ph.D. stepped down effective August 28, 2023, with a severance agreement pending under the company's Executive Severance Plan. CEO Jeffrey Hawkins was appointed to also assume the role of President with no additional compensation, retaining his existing CEO and board positions.
2023-08-07
Earnings
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on August 7, 2023, disclosing its financial results for the second quarter ended June 30, 2023, along with a business update. The filing was signed by General Counsel Christian LaPointe, Ph.D., and includes a press release as Exhibit 99.1. No specific revenue or earnings figures were detailed within the 8-K itself, as the results were contained in the attached press release.
2023-07-20
LeadershipEquity Grant
Quantum-Si Incorporated disclosed the departure of Michael P. McKenna, Ph.D., Executive Vice President of Product Development and Operations, with his employment terminating on July 31, 2023. Under the Separation Agreement dated July 18, 2023, McKenna will receive $337,500 in severance pay, employer-covered COBRA health insurance through up to April 30, 2024, and accelerated vesting of 227,083 stock options, 747,656 restricted stock awards, and 44,862 restricted stock units, with all remaining equity awards forfeited. The agreement also includes a release and waiver by McKenna.
2023-06-21
Agreement
Quantum-Si Incorporated disclosed that Michael P. McKenna, Ph.D., its Executive Vice President of Product Development and Operations, will step down from his role effective July 31, 2023, following a mutual agreement reached on June 16, 2023. The company expects to enter into a separation agreement with Dr. McKenna consistent with its Executive Severance Plan, the terms of which will be disclosed once finalized.
2023-06-07
LeadershipEquity Grant
Quantum-Si Incorporated disclosed the departure of Claudia Drayton, its former Chief Financial Officer and Treasurer, who stepped down on May 12, 2023, and will fully separate from the company on June 30, 2023. Under the Separation Agreement signed June 1, 2023, Drayton will receive $300,000 in separation pay, company-paid COBRA health coverage through up to March 31, 2024, and vesting of 229,037 stock options and 47,852 restricted stock units, with all remaining equity awards forfeited. The agreement also includes a release and waiver by Drayton of claims against the company.
2023-05-22
Listing Risk
Quantum-Si Incorporated appointed John Patrick ("Jack") Kenny to its Board of Directors, effective May 19, 2023, also naming him to the Nominating and Corporate Governance Committee and Compensation Committee. Kenny, age 54, brings over 30 years of healthcare industry experience, including his current role as CEO of Meridian Bioscience Inc. since October 2017, and prior leadership positions at Siemens Healthcare, Becton Dickinson, Danaher Corporation, and Quest Diagnostics. He will receive standard non-employee director compensation on a pro-rated basis and has been determined to be an independent director under Nasdaq listing rules.
2023-05-16
8-K
At its 2023 Annual Meeting on May 11, 2023, Quantum-Si Incorporated shareholders approved four proposals, including the reelection of seven board members, ratification of Deloitte & Touche LLP as auditor, an advisory say-on-pay vote, and an amendment to the company's certificate of incorporation. The Charter Amendment, filed with the Delaware Secretary of State on May 12, 2023, limits officer liability as permitted under recent changes to Delaware law. Approximately 92% of total voting power was represented at the meeting, with roughly 79.3 million Class A shares and 19.9 million Class B shares present or by proxy.
2023-05-11
Earnings
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on May 11, 2023, disclosing its financial results for the first quarter ended March 31, 2023, along with a business update. The press release accompanying the filing was furnished as Exhibit 99.1 and signed by General Counsel Christian LaPointe, Ph.D. No specific revenue or earnings figures were included in the 8-K body itself, with the detailed results contained in the attached press release.
2023-05-02
Equity Grant
Quantum-Si Incorporated appointed Jeffry Keyes as Chief Financial Officer and Treasurer, effective on or before May 15, 2023, replacing Claudia Drayton, who mutually agreed to step down as CFO and Treasurer as of the same date and will serve as a senior advisor through June 30, 2023. Keyes, age 50, will receive an annual base salary of $465,000, a target bonus of 50% of base salary, and equity inducement awards totaling 2,000,000 stock options with time-based and performance-based vesting conditions tied to Class A common stock price targets of $10.00 and $20.00. Drayton's separation terms will follow the company's Executive Severance Plan and will be disclosed once finalized.
2023-03-15
8-K
On March 14, 2023, the Delaware Court of Chancery approved Quantum-Si Incorporated's petition under Section 205 of the DGCL, validating the company's Second Amended and Restated Certificate of Incorporation retroactive to its original filing date of June 10, 2021. The ruling also confirmed the validity of all securities issued in reliance on that certificate, resolving uncertainty stemming from an earlier Court of Chancery decision. The filing was signed by CFO Claudia Drayton on March 15, 2023.
2023-03-13
IR Event
Quantum-Si Incorporated filed this 8-K on March 13, 2023, to disclose that the FDIC was appointed as receiver for Silicon Valley Bank on March 10, 2023. The company clarified that it holds no deposits, securities, or accounts at Silicon Valley Bank and therefore faces no direct exposure from the bank's failure. The filing was signed by CFO Claudia Drayton and was made solely to address potential investor concerns about liquidity risk.
2023-03-06
Earnings
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on March 6, 2023, disclosing its financial results for Q4 and the full year ended December 31, 2022, via a press release. The filing was signed by CFO Claudia Drayton and includes the earnings press release as Exhibit 99.1. No specific financial figures were detailed within the 8-K body itself, as the results are contained in the attached press release.
2023-03-02
8-K
Quantum-Si Incorporated filed an 8-K on February 28, 2023, disclosing that it petitioned the Delaware Court of Chancery under Section 205 of the DGCL to validate charter amendments originally approved at a June 9, 2021 stockholder meeting, which may not have complied with separate class voting requirements under Section 242(b)(2) of the DGCL. The petition seeks retroactive validation of the company's Second Amended and Restated Certificate of Incorporation and all securities issued in reliance on it. A hearing was scheduled for March 14, 2023, with the Court of Chancery having granted the company's motion to expedite on March 1, 2023.
2023-01-30
Earnings
On January 30, 2023, Quantum-Si Incorporated announced a workforce restructuring to reduce costs and streamline operations, resulting in the termination of approximately 12% of its employees effective in Q1 2023. The company expects to incur up to $1.0 million in restructuring costs, consisting primarily of cash severance and related benefits. The restructuring is expected to be substantially completed within Q1 2023, and the filing was signed by CFO Claudia Drayton.
2023-01-12
IR Event
Quantum-Si Incorporated disclosed via Regulation FD that it was scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 1:30 PM Eastern Time. The filing was signed by CFO Claudia Drayton, and presentation slides were made available on the company's investor relations website. No financial figures or material transactions were disclosed.
2023-01-09
Agreement
On January 9, 2023, Quantum-Si Incorporated announced it had begun commercial shipments of its Platinum™ protein sequencing system and revealed new partnerships. The company's management presented these updates at the 41st Annual J.P. Morgan Healthcare Conference. The filing was signed by CFO Claudia Drayton and disclosed under Regulation FD (Item 7.01).
2022-12-20
8-K
On December 20, 2022, Quantum-Si Incorporated announced the commercial availability of its Platinum™ platform, described as the world's first next-generation single-molecule protein sequencing system. The filing was signed by CFO Claudia Drayton and accompanied by a press release attached as Exhibit 99.1. No financial figures were disclosed in the filing itself.
2022-11-07
Earnings
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on November 7, 2022, disclosing its financial results for the third quarter ended September 30, 2022, along with a business update. The filing was signed by CFO Claudia Drayton and accompanied by a press release furnished as Exhibit 99.1. No specific financial figures were included in the 8-K itself, as the detailed results were contained in the attached press release.
2022-10-04
LeadershipEquity Grant
Quantum-Si Incorporated appointed Jeffrey Hawkins, age 44, as Chief Executive Officer effective October 10, 2022, replacing Jonathan Rothberg, Ph.D., who had been serving as Interim CEO and will remain Executive Chairman. Hawkins' compensation package includes a $575,000 annual base salary, a 100% target bonus, a $150,000 sign-on bonus, and equity awards totaling 6,950,000 stock options (comprising 4,170,000 time-based and 2,780,000 performance-based options tied to stock price thresholds of $10.00 and $20.00). The Board also expanded from seven to eight members to accommodate Hawkins' concurrent appointment as a director.
2022-08-08
Earnings
Quantum-Si Incorporated (QSI) filed an 8-K on August 8, 2022, disclosing its financial results for the second quarter ended June 30, 2022, along with a business update. The press release accompanying the filing was furnished as Exhibit 99.1 and signed by CFO Claudia Drayton. No specific financial figures were included in the filing itself, as the detailed results were contained in the attached press release.
2022-06-16
8-K
Quantum-Si Incorporated appointed Vikram Bajaj, Ph.D. to its Board of Directors, effective June 15, 2022, also expanding the Board from six to seven members. Dr. Bajaj, Managing Director of Foresite Capital Management (a 5%+ shareholder) and CEO of Foresite Labs, will serve on the Compensation Committee and receive standard nonemployee director compensation. He will serve until the company's next annual meeting of stockholders.
2022-06-10
LeadershipAgreement
Quantum-Si Incorporated disclosed that Matthew Dyer, Ph.D. resigned as Chief Business Officer effective June 15, 2022. The company entered into a separation agreement with Dr. Dyer dated June 10, 2022, under which he will receive $300,000 in severance (equal to nine months of his base salary) and company-paid COBRA health insurance coverage from July 1, 2022 through March 31, 2023. The agreement is contingent on Dr. Dyer not revoking it on or before June 17, 2022.
2022-05-16
8-K
Quantum-Si Incorporated held its 2022 Annual Meeting of Stockholders on May 10, 2022, at which approximately 91.39% of total voting power was represented. Stockholders reelected six board directors including Jonathan M. Rothberg, Ph.D., ratified Deloitte & Touche LLP as the company's independent auditor for fiscal year 2022, and approved an annual frequency for future advisory votes on named executive officer compensation. The filing was signed by CFO Claudia Drayton on May 16, 2022.
2022-05-09
EarningsEquity Grant
Quantum-Si Incorporated announced that Patrick Schneider was appointed President and Chief Operating Officer effective May 9, 2022, while Michael P. McKenna, Ph.D. transitioned to Executive Vice President, Product Development and Operations effective May 6, 2022. Schneider's compensation includes a $475,000 annual base salary, a 75% target bonus, a $400,000 sign-on bonus, and equity awards totaling 2,000,000 stock options (including 1,000,000 time-based and 1,000,000 performance-based options tied to stock price targets of $10 and $20). The company also disclosed its Q1 2022 financial results via a separate press release issued on May 9, 2022.
2022-03-08
IR Event
Quantum-Si Incorporated (QSI) filed this 8-K on March 8, 2022, to disclose that it presented at the 42nd Annual Cowen Health Care Conference on that date. The presentation, a business update for the investment community, was made available on the company's investor relations website and filed as Exhibit 99.1. The filing was signed by CFO Claudia Drayton and is furnished under Regulation FD, meaning it is not deemed "filed" for liability purposes under the Exchange Act.
2022-02-28
Earnings
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on February 28, 2022, disclosing its financial results for the fourth quarter and full year ended December 31, 2021, via a press release. The filing was signed by CFO Claudia Drayton and includes the earnings press release as Exhibit 99.1. No specific revenue or earnings figures were included in the 8-K body itself, as the detailed results are contained in the attached press release.
2022-02-14
LeadershipEquity GrantAgreement
Quantum-Si Incorporated disclosed that CEO John Stark resigned effective February 8, 2022, to pursue outside opportunities, and simultaneously stepped down from the Board of Directors. Under a separation agreement dated February 11, 2022, Stark will receive total payments of approximately $1,102,750, comprising $500,000 in severance, a $352,750 annual bonus for 2021, and a $250,000 special bonus, contingent on him not revoking the agreement by February 18, 2022. Executive Chairman Jonathan M. Rothberg, Ph.D. was appointed Interim CEO effective the same date, receiving no additional compensation, while the company conducts a search for a permanent replacement.
2022-01-12
AgreementIR Event
Quantum-Si Incorporated (Nasdaq: QSI) disclosed via Regulation FD that it was scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 4:30 PM Eastern Time. The filing, signed by CEO John Stark, noted that presentation slides would be made available on the company's investor relations website. No financial transactions, agreements, or material business changes were announced.
2022-01-10
8-K
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on January 10, 2022, disclosing that its management would present business updates at the 40th Annual J.P. Morgan Healthcare Conference. The filing was made under Regulation FD and accompanied by a press release. The report was signed by CEO John Stark.
2022-01-04
Agreement
On December 28, 2021, Quantum-Si Incorporated entered into a 10-year lease agreement with Winchester Office LLC for approximately 65,000 square feet at 115 Munson Street in New Haven, Connecticut, which will serve as the company's new headquarters. Base rent is set at $191,071.50 per month, beginning 180 days after the landlord delivers possession, and increases 2.5% annually, with the company also responsible for 52.60% of operating expenses. Quantum-Si paid a security deposit of $573,214.50 at signing and holds two five-year renewal options.
2021-11-10
Earnings
On November 10, 2021, Quantum-Si Incorporated disclosed its financial results for the third quarter ended September 30, 2021 via a press release. The filing was signed by CEO John Stark and submitted under Item 2.02 (Results of Operations and Financial Condition). No specific financial figures were included in the 8-K body itself; the detailed results were furnished as Exhibit 99.1.
2021-10-19
8-K
On October 19, 2021, Quantum-Si Incorporated (Nasdaq: QSI) disclosed via an 8-K under Regulation FD that it is expanding its early access program for the Platinum™ Single Molecule Protein Sequencing Platform. The filing was signed by CEO John Stark and is based in Guilford, Connecticut. No financial figures were disclosed, as the announcement was furnished rather than filed and consisted solely of a press release attached as Exhibit 99.1.
2021-09-29
AgreementIR Event
Quantum-Si Incorporated (QSI) filed an 8-K on September 29, 2021, disclosing under Regulation FD that it updated and published a new corporate presentation available on its investor relations website. The filing, signed by CEO John Stark, furnished the presentation as Exhibit 99.1 and notes it is not deemed "filed" for liability purposes under the Securities Exchange Act. No financial transactions, material agreements, or specific financial figures were disclosed.
2021-09-24
8-K
On September 20, 2021, Quantum-Si Incorporated entered into a Binders Collaboration with Protein Evolution, Inc. (PEI) to develop nanobodies and other biological reagents over a 24-month period, with Quantum-Si paying up to $13.5 million for the services. The agreement is a related-party transaction, as Quantum-Si's Executive Chairman Dr. Jonathan M. Rothberg serves as Chairman of PEI's board and the Rothberg family are controlling stockholders of both companies; the deal was pre-approved by Quantum-Si's audit committee. Under the arrangement, Quantum-Si will own all intellectual property in the resulting reagents, while PEI retains rights to process results with cross-licenses granted to each party.
2021-08-16
Earnings
Quantum-Si Incorporated (Nasdaq: QSI) filed an 8-K on August 16, 2021, disclosing its financial results for the second quarter ended June 30, 2021, along with a business update via press release. The filing was signed by CEO John Stark and pertains solely to the results of operations under Item 2.02. No specific financial figures were included in the 8-K body itself; the detailed results were contained in the attached Exhibit 99.1 press release.
2021-07-06
8-K
Quantum-Si Incorporated's Board of Directors adopted an Executive Severance Plan on June 29, 2021, providing termination and change-in-control benefits — including salary continuation, accelerated equity vesting, and COBRA coverage — to the CEO and other executive officers. The Board also approved a compensation increase for CEO John Stark, raising his annual base salary from $350,000 to $500,000 effective July 1, 2021, and increasing his target annual bonus from 60% to 100% of base salary beginning with 2021 performance.
2021-06-25
8-K
Quantum-Si Incorporated's Compensation Committee approved salary increases for three executive officers, effective July 1, 2021: CFO Claudia Drayton's base salary rose from $330,000 to $385,000, President and COO Michael P. McKenna's from $275,000 to $440,000, and Chief Business Officer Matthew Dyer's from $275,000 to $400,000. The Committee also established target annual performance bonuses of 50% of base salary for McKenna and Dyer beginning with 2021 performance, while retaining Drayton's existing 50% bonus target. The changes were approved on June 24, 2021, and reported in the filing signed by CEO John Stark on June 25, 2021.
2021-06-24
Agreement
Quantum-Si Incorporated entered into a lease agreement on June 18, 2021, with landlord BP3-SD5 5510 Morehouse Drive LLC for approximately 25,586 square feet on the 4th floor of 5510 Morehouse Drive, San Diego, California, to serve as the company's product development and operations facility. The initial lease term is six years and four months beginning September 1, 2021, with an option to extend for one additional five-year period. Monthly base rent starts at approximately $117,183.88, increasing 3% annually, with a security deposit of the same amount, plus the company's 23.74% proportionate share of additional operating expenses.
2021-06-15
Agreement
On June 10, 2021, HighCape Capital Acquisition Corp. completed its merger with Quantum-Si Incorporated, with HighCape subsequently renaming itself "Quantum-Si Incorporated" (ticker: QSI) and the legacy company becoming "Q-SI Operations Inc." as a wholly-owned subsidiary. The Business Combination was governed by an agreement dated February 18, 2021, with Legacy Quantum-Si shares converted into Company stock at an exchange ratio of 0.7975, based on an implied enterprise value of $810 million. Following the closing, QSI's Class A common stock and redeemable warrants (exercisable at $11.50 per share) began trading on the Nasdaq Stock Market.
2021-06-15
IR Event
Quantum-Si Incorporated filed an 8-K on June 15, 2021, disclosing an updated corporate presentation made available to the investment community on its investor relations website. The filing was signed by CEO John Stark and the presentation is included as Exhibit 99.1. The disclosure was made under Regulation FD and is furnished rather than filed, meaning it is not subject to Exchange Act Section 18 liability.
2021-06-09
Equity GrantAgreement
HighCape Capital Acquisition Corp. held a Special Meeting on June 9, 2021, at which stockholders approved a business combination with Quantum-Si Incorporated, a Delaware corporation, pursuant to a Business Combination Agreement dated February 18, 2021, whereby Quantum-Si will survive as a wholly owned subsidiary of HighCape. The Business Combination Proposal passed with 8,645,618 votes in favor and 51,891 against, out of 8,709,297 shares (58.93% of outstanding shares) present at the meeting. Stockholders also approved related charter amendments, including increasing authorized capital stock to 628,000,000 shares and establishing a dual-class voting structure giving Class B common stock 20 votes per share versus one vote per share for Class A common stock.
2021-06-08
EarningsOffering
HighCape Capital Acquisition Corp. filed this 8-K on June 7, 2021 to voluntarily supplement its Definitive Proxy Statement/Prospectus ahead of a June 9, 2021 shareholder vote on its proposed merger with Quantum-SI Incorporated, following demand letters from purported shareholders alleging disclosure deficiencies. The supplemental disclosures clarify J.P. Morgan's dual role as PIPE placement agent and M&A advisor (retained January 29, 2021) with contingent fees tied to the deal's closing, and provide additional comparable company valuation metrics including EV/2023E Revenue multiples ranging from 10.2x to 145.5x across peer companies. HighCape denies any wrongdoing and states the supplemental disclosures are being made solely to avoid delays to the Business Combination.
2021-05-10
Restatement
HighCape Capital Acquisition Corp. filed this 8-K on May 5, 2021, disclosing that it must restate its previously issued financial statements after determining its warrants should be reclassified from equity to derivative liabilities, following an April 12, 2021 SEC staff statement on SPAC warrant accounting. The restatement affects audited financials as of December 31, 2020 and interim periods back to September 2020, with the Company planning to file an amended Form 10-K. This filing also notes HighCape's pending business combination with Quantum-Si Incorporated, for which a Form S-4 registration statement had already been filed with the SEC.
2021-02-23
8-K
On February 19, 2021, HighCape Capital Acquisition Corp. entered into a Transaction Support Agreement with Dr. Jonathan M. Rothberg and certain affiliated stockholders of Quantum-SI Incorporated, under which those stockholders agreed to vote in favor of a Business Combination Agreement dated February 18, 2021 between HighCape, Tenet Merger Sub, Inc., and Quantum-SI. The supporting stockholders also agreed to transfer restrictions on their Quantum-SI equity and to vote against competing acquisition proposals prior to the deal's closing. The filing signals a SPAC merger between HighCape (Nasdaq: CAPA) and Quantum-SI, with a Form S-4 registration statement to be filed with the SEC ahead of a stockholder vote.
2021-02-18
Agreement
On February 18, 2021, HighCape Capital Acquisition Corp. entered into a Business Combination Agreement with Quantum-SI Incorporated, under which HighCape's merger subsidiary will merge with and into Quantum-SI, making Quantum-SI a wholly owned subsidiary and renaming the combined company "Quantum-SI Incorporated." The deal, unanimously approved by HighCape's board on February 18, 2021, includes a dual-class share structure with Class A stock carrying one vote per share and Class B stock carrying 20 votes per share, with the Class B shares subject to a sunset provision tied to founder Dr. Jonathan M. Rothberg maintaining at least 20% of Class B shares. The transaction is subject to approval by HighCape's stockholders before it can be consummated.
2020-10-23
8-K
HighCape Capital Acquisition Corp. announced on October 23, 2020 that holders of its units (ticker: CAPAU) could begin separately trading the Class A common stock (CAPA) and redeemable warrants (CAPAW) on Nasdaq on or about October 26, 2020. Each unit consists of one share of Class A common stock and one-third of a redeemable warrant exercisable at $11.50 per share. Unit holders wishing to separate their securities needed to contact Continental Stock Transfer & Trust Company through their brokers to complete the separation.
2020-09-15
8-K
HighCape Capital Acquisition Corp. completed its IPO on September 9, 2020, selling 11,500,000 units at $10.00 per unit and generating $115,000,000 in gross proceeds, with the underwriter fully exercising its over-allotment option. Simultaneously, sponsor HighCape Capital Acquisition LLC purchased 405,000 private placement units at $10.00 each for an additional $4,050,000. The full $115,000,000 was placed in a trust account at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer & Trust Company acting as trustee.
2020-09-09
8-K
HighCape Capital Acquisition Corp. completed its IPO on September 9, 2020, selling 11,500,000 units at $10.00 per unit and raising gross proceeds of $115,000,000, with Cantor Fitzgerald & Co. serving as underwriter. Simultaneously, the company's sponsor, HighCape Capital Acquisition LLC, purchased 405,000 private placement units at $10.00 each in a separate transaction generating an additional $4,050,000. In connection with the IPO, David Colpman, Antony Loebel, and Robert Taub were appointed as independent directors to the board effective September 3, 2020.

Source: SEC EDGAR · Material events, earnings releases, contract announcements · Updated weekly

S-3 shelf registrations, 424B prospectuses, and document-verified foreign-issuer supplements represent potential dilution events. Quantum-Si has 29 such filings on record.

All Shelf Filings ↗
2025-10-29424B3QSI launches $100M ATM offering via Leerink Partners at ~$2.18/share, adding ~45.9M new shares.
ATMLarge ($50M+)DilutiveShelf
2025-10-09S-3/AQSI files amended $300M shelf with $100M ATM via Leerink Partners for product dev & working capital.
ShelfATMAmendmentLarge ($50M+)Dilutive
2025-09-26S-3QSI files $300M shelf with $100M ATM via Leerink Partners for product development & general corporate use.
ShelfATMLarge ($50M+)Dilutive
2025-07-07424B5QSI raises ~$47M net via registered direct offering of 18.2M shares + pre-funded warrants at $1.67
PIPEUnderwrittenMid ($10-50M)DilutiveShelf
2025-07-07424B5QSI suspends $75M ATM offering effective July 3, 2025 — no further sales until new prospectus filed.
ATMAmendmentLarge ($50M+)Shelf
2025-01-06424B5QSI raises $50M via registered direct offering of 15.6M shares at $3.20, a 25% discount to last close.
PIPEUnderwrittenLarge ($50M+)DilutiveShelf
2024-12-11424B5QSI launches $75M ATM offering via Canaccord at ~$2.26/share to fund Proteus platform development.
ATMShelfLarge ($50M+)Dilutive
2023-08-11S-3QSI files $150M shelf with $75M ATM tranche via Evercore for commercialization & R&D funding.
ShelfATMLarge ($50M+)Dilutive
2022-07-20424B3QSI registers 92M+ shares & warrants for resale by insiders/PIPE investors; up to $45.6M from warrant exercises.
ShelfSecondaryMerger SharesPIPEWarrant Registration
2022-07-20424B3QSI registers 92M+ shares & warrants for resale post-SPAC merger; minimal new cash to company
ShelfSecondaryWarrant RegistrationMerger SharesPIPE
2022-06-16424B3QSI Prospectus Supplement No. 6: Resale of ~99M shares & 135K warrants from SPAC merger; board adds Vikram Bajaj.
SecondaryWarrant RegistrationMerger SharesShelfDilutive
2022-06-16424B3QSI Prospectus Supplement No. 6: Resale of up to ~99M shares post-SPAC merger; warrants exercisable at $11.50 vs. $3.36 stock price.
Warrant RegistrationSecondaryMerger SharesShelfDilutive
2022-06-10424B3QSI Prospectus Supplement No. 5: Resale of ~99M shares and 135K warrants from SPAC merger, no new cash raised.
SecondaryMerger SharesWarrant RegistrationShelfDilutive
2022-06-10424B3QSI resale shelf supplement #5: ~99M legacy shares & warrants registered post-SPAC merger, no new cash raised.
SecondaryMerger SharesShelfWarrant RegistrationDilutive
2022-05-16424B3QSI Prospectus Supplement No. 4: Resale of ~99M shares & 135K warrants post-SPAC merger, no new cash raised.
SecondaryWarrant RegistrationMerger SharesShelfDilutive
2022-05-16424B3QSI resale shelf supplement: up to 78.8M Class A & 19.9M Class B shares plus warrants registered for selling shareholders.
SecondaryMerger SharesWarrant RegistrationShelfDilutive
2022-05-10424B3QSI Prospectus Supplement No. 3: Resale of ~99M shares & 135K warrants from SPAC merger; no new capital raised.
ResaleWarrant RegistrationMerger SharesShelfSecondary
2022-05-10424B3QSI 424B3 Supplement: Resale shelf update covering ~99M shares & warrants post-SPAC merger, no new cash raised.
SecondaryShelfMerger SharesWarrant Registration
2022-05-09424B3QSI files 424B3 supplement to resale shelf — up to ~99M shares eligible for resale by insiders/PIPE investors.
SecondaryShelfAmendmentWarrant RegistrationDilutive
2022-05-09424B3QSI files 424B3 supplement covering ~99M resale shares & warrants from SPAC merger; no new cash raised.
SecondaryMerger SharesWarrant RegistrationShelfDilutive
2022-03-14424B3QSI updates resale prospectus to add 405K Class A shares held by SPAC sponsor HighCape Capital Acquisition LLC.
SecondaryMerger SharesShelfAmendmentWarrant Registration
2022-03-04424B3QSI registers 98M+ shares & 135K warrants for resale post-SPAC merger; up to $45.6M from warrant exercises.
Warrant RegistrationSecondaryMerger SharesPIPEDilutive
2022-01-04424B3QSI Prospectus Supplement No. 5: Resale of ~121M shares + warrants from SPAC merger, no new cash raised.
SecondaryMerger SharesShelfWarrant RegistrationDilutive
2021-11-19424B3QSI updates resale prospectus to reflect insider share transfers — no new capital raised.
SecondaryMerger SharesWarrant RegistrationShelf
2021-11-15424B3QSI Prospectus Supplement No. 3: Resale of ~121M shares & 135K warrants post-SPAC merger; no new cash raised.
SecondaryMerger SharesWarrant RegistrationShelfDilutive
2021-09-24424B3QSI resale shelf supplement: up to ~121M shares & 135K warrants registered for selling shareholders post-SPAC merger.
Warrant RegistrationSecondaryMerger SharesShelfDilutive
2021-08-16424B3QSI resale shelf supplement registers 121M+ shares post-SPAC merger with HighCape; no new cash raised by company.
ResaleMerger SharesPIPEWarrant RegistrationShelf
2021-07-22424B3QSI post-SPAC resale shelf: up to 121M shares & 135K warrants hit the market after HighCape merger
Merger SharesPIPEWarrant RegistrationSecondaryDilutive
2021-05-14424B3QSI goes public via SPAC merger with HighCape; $425M PIPE at $10/share funds the deal.
Merger SharesPIPELarge ($50M+)Dilutive

Source: SEC EDGAR · S-3 = shelf registration, 424B3/B5 = active offering (dilutive)

Ownership & Insiders

SC 13G/D filers · >5% ownership

All 13G/D ↗
InstitutionForm% OwnedFiled
VANGUARD GROUPSC 13G/A4.77%2025-10-30
VANGUARD HORIZON FUNDSSC 13G5.30%2025-07-29
SC 13G7.00%2024-02-05
BLACKROCK ADVISORSSC 13G/A6.10%2024-01-29
BlackRock,SC 13G/A2.30%2026-07-29

Source: SEC EDGAR SC 13G/D · Updated monthly

Open-market buys and sells by directors and officers

All Form 4s ↗

90-Day Activity

8S
0 buys8 saleslast 90 days
FiledInsiderTypeSharesPrice
2026-06-24Hawkins Jeffrey Alan▼ SELL11,311$0.8990
2026-06-24Hawkins Jeffrey Alan▼ SELL11,310$0.9574
2026-06-24Vieceli John S.▼ SELL15,112$0.8990
2026-06-24Vieceli John S.▼ SELL15,111$0.9574
2026-06-24Keyes Jeffry R.▼ SELL4,117$0.8990
2026-06-24Keyes Jeffry R.▼ SELL4,116$0.9574
2026-06-24LaPointe Christian▼ SELL7,794$0.8990
2026-06-24LaPointe Christian▼ SELL7,794$0.9574
2026-04-22Hawkins Jeffrey Alan▼ SELL83,712$0.9950
2026-04-22Hawkins Jeffrey Alan▼ SELL83,712$1.01
2026-04-22Keyes Jeffry R.▼ SELL37,381$0.9950
2026-04-22Keyes Jeffry R.▼ SELL37,382$1.01
2026-03-24Hawkins Jeffrey Alan▼ SELL12,149$0.8266
2026-03-24Hawkins Jeffrey Alan▼ SELL11,628$0.8483
2026-03-24Vieceli John S.▼ SELL11,239$0.8266
2026-03-24Vieceli John S.▼ SELL10,758$0.8483
2026-03-24LaPointe Christian▼ SELL6,110$0.8266
2026-03-24LaPointe Christian▼ SELL5,849$0.8483
2026-03-24Keyes Jeffry R.▼ SELL4,422$0.8266
2026-03-24Keyes Jeffry R.▼ SELL4,233$0.8483
2026-03-16LaPointe Christian▲ BUY261,121
2026-03-16Hawkins Jeffrey Alan▲ BUY1,305,606
2026-03-16Vieceli John S.▲ BUY391,681
2026-03-16Keyes Jeffry R.▲ BUY652,803
2026-03-09Dowdy Paula▲ BUY109,890$0.9505
2026-03-09Kummeth Charles R.▲ BUY500,000$0.9196
2025-12-22Hawkins Jeffrey AlanDIR▼ SELL23,707$1.28
2025-12-22Keyes Jeffry R.▼ SELL8,627$1.28
2025-12-22LaPointe Christian▼ SELL11,951$1.28
2025-12-22Vieceli John S.▼ SELL21,927$1.28

Source: SEC EDGAR Form 4 · Open-market buys and sells · Updated daily

Bull vs Bear: Analyst Opinions on Quantum-Si (QSI)

Generated from live analyst targets, SEC filings and market data as of August 2026 — not investment advice.

▲ THE BULL CASE

• Wall Street's mean price target of $2.50 implies 235% upside — consensus rating Buy across 3 analysts.

• 2 of 3 analyst ratings are Buy or Strong Buy.

• $381.06K in U.S. federal contracts and grants across 5 awards validates the technology with government customers.

• Retail sentiment on StockTwits runs 78% bullish over the last 9 scored posts.

▼ THE BEAR CASE

• Revenue declined 20% year-over-year to $2.44M (latest fiscal year).

• Only about 16 months of cash runway at the current burn rate — a capital raise (and dilution) is likely.

• 29 at-the-market / shelf offering filings (S-3 / 424B / SUPPL) on record — an active dilution channel.

• 66.7% of daily trading volume is short selling (FINRA), signaling heavy bearish positioning.

• Not yet profitable: net loss of $101.34M in the latest fiscal year.

How long is Quantum-Si's (QSI) cash runway?

Quantum-Si has roughly 16 months of cash runway as of August 2026 — $127.38M in cash divided by its trailing-twelve-month operating burn.

How much government funding has Quantum-Si received?

Quantum-Si has received $381.06K in U.S. federal contracts and grants across 5 tracked awards (USAspending.gov).

Is QSI stock at risk of shareholder dilution?

Dilution risk is elevated: 29 shelf/ATM offering filings on record, only ~16 months of cash runway.

What percentage of QSI's trading volume is short?

66.7% of QSI's daily trading volume was short selling as of 2026-07-29 (FINRA daily short volume).

Compare QSI with other quantum computing stocks